Matinas BioPharma's at-the-market sales pact with BTIG terminated
BTIG ended the $50 million equity sales agreement effective immediately, with no penalties owed by Matinas.
SEC filing
Latest
2 stories
Friday, July 24
Monday, July 13
Matinas to combine with GH Power, sell drug unit MAT2203 to Azurity
The biopharma company plans to become a clean energy business through a merger while divesting its lead antifungal candidate in a separate deal worth up to $21.5 million.
SEC filing